Wall Street Inches Closer to a Staked Injective ETF—Because What’s Finance Without More Complexity?

Delaware just became crypto’s favorite playground—again. Canary Capital quietly filed paperwork for a staked Injective (INJ) trust, teeing up what could be the first ETF to bake in yield-generating mechanics. Move over, Bitcoin futures—this is DeFi’s backdoor into traditional markets.

Why it matters: Staking rewards meet institutional packaging. The filing signals growing demand for ‘productive’ crypto assets—tokens that don’t just sit there like deadweight gold ETFs. But let’s be real: Wall Street won’t touch this unless they can slap a 2% management fee on it.

The catch? Regulatory limbo. The SEC still treats staking like a securities minefield. But with Ethereum ETFs already live, the agency’s resistance looks increasingly performative. Meanwhile, TradFi quietly copies crypto’s homework—with extra middlemen, of course.

Bottom line: The ETF arms race just got weirder. Whether this becomes a product or just another filing graveyard depends on how badly asset managers want to justify their existence in 2025. Place your bets—the house always wins.